Cargando…
Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR
Most lung cancer patients are diagnosed at an advanced stage, limiting their treatment options with very low response rate. Lung cancer is the most common cause of cancer death worldwide. Therapies that target driver gene mutations (e.g. EGFR, ALK, ROS1) and checkpoint inhibitors such anti-PD-1 and...
Autores principales: | Alwithenani, Akram, Bethune, Drew, Castonguay, Mathieu, Drucker, Arik, Flowerdew, Gordon, Forsythe, Marika, French, Daniel, Fris, John, Greer, Wenda, Henteleff, Harry, MacNeil, Mary, Marignani, Paola, Morzycki, Wojciech, Plourde, Madelaine, Snow, Stephanie, Marcato, Paola, Xu, Zhaolin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8101740/ https://www.ncbi.nlm.nih.gov/pubmed/33956842 http://dx.doi.org/10.1371/journal.pone.0251080 |
Ejemplares similares
-
Molecular profiling of non-small cell lung cancer
por: Forsythe, Marika L., et al.
Publicado: (2020) -
Standardization of PD-L1 immunohistochemistry
por: Martinez-Morilla, Sandra, et al.
Publicado: (2021) -
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017) -
Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD‐L1 immunohistochemistry for predicting response to anti‐PD‐1/PD‐L1 immunotherapy
por: Hu, Weixian
Publicado: (2019) -
PD-L1 testing by immunohistochemistry in immuno-oncology
por: Vranic, Semir, et al.
Publicado: (2023)